Compounds according to Formula I are potent inhibitors of PSMA activity:The invention also provides pharmaceutical compositions of a complex of a radionuclide and a Formula I compound and methods of using the radionuclide complex of a Formula I compound for treating or diagnosis of a disease or a condition associated with PSMA activity.